NEW YORK (GenomeWeb) – Mobidiag, a Finnish molecular diagnostics maker, has entered an agreement with Chinese clinical diagnostics firm Autobio Diagnostics to establish a joint venture in China. Separately, Autobio Diagnostics has made a €10 million ($11.3 million) equity investment in Mobidiag, the firms announced today.
Mobidiag and Autobio will invest a total of €12.3 million to establish the joint venture company, with Autobio investing €8 million in the JV for a 65 percent stake, and Mobidiag investing €4.3 million for a 35 percent stake.